DOCSLIB.ORG

United States Patent (19) 11 Patent Number: 5,389,623 Bodor 45 Date of Patent: Feb

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11 Patent Number: 5,389,623 Bodor 45 Date of Patent: Feb US005389.623A United States Patent (19) 11 Patent Number: 5,389,623 Bodor 45 Date of Patent: Feb. 14, 1995 (54) REDOX CARRIERS FOR BRAIN-SPECIFIC DRUG DELVERY OTHER PUBLICATIONS Wu et al., CA 77: 19978m (1972). 75) Inventor: Nicholas S. Bodor, Gainesville, Fla. Endo et al, CA 92: 21076y (1979). 73) Assignee: University of Florida, Gainesville, Endo et al, CA 87: 53561m (1977). Fla. Bodor et al, Science 190, 155-156 (1975). Shek et al., J. Med. Chem. 19, 113-117 (1976). 21 Appl. No.: 766,528 Bodor et al, in Design of Biopharmaceutical Properties through Prodrugs and Analogs, ed. Edward B. Roche, (22 Filed: Sep. 27, 1991 American Pharmaceutical Association, Washington, D.C., 98-135 (1977). Related U.S. Application Data Bodor et al, J. Pharm. Sci 67, 685-687 (1978). 60 Division of Ser. No. 295,663, Jan. 11, 1989, Pat. No. Bodor et al, Science 214, 1370-1372 (1981). 5,087,618, which is a division of Ser. No. 666,210, Oct. The Friday Evening Post, Health Center Communica 29, 1984, Pat. No. 4,829,070, which is a continuation-in tions, University of Florida, Gainesville, Fla., Aug. 14, part of Ser. No. 379,316, May 18, 1982, Pat. No. 1981. 4,479,932, and Ser. No. 461,543, Jan. 27, 1983, aban Chemical and Engineering News, pp. 24-25, Dec. 21, doned, and Ser. No. 475,493, Mar. 15, 1983, Pat. No. 1981. 4,622,218, and a continuation-in-part of Ser. No. Science News, vol. 121, #1, p. 7, Jan. 2, 1982. 516,382, Jul. 22, 1983, Pat. No. 4,540,564. Brewster III, Dis. Abst. Int. B., vol. 43, #9, p. 2910B (30) Foreign Application Priority Data (1983). Bodor et al., J. Med. Chem. 26, 313-318 (1983). May 12, 1983 WO WIPO ................. PCT/US83/00725 Bodor et al, J. Med. Chem. 26, 528-534 (1983). May 16, 1983 CA) Canada ................................... 428.192 Bodor et al, Pharmac. Ther. 19, 337-386 (1983). 51 Int. Cl. .................... A61K 31/56; A61K 31/455 Bodor et al, J. Pharm. Sci 73, 385-389 (1984). 52 U.S.C. .................................... 514/169; 514/170; Bodor et al, Science 221, 65-67 (1983). 514/356; 540/109; 540/110 Primary Examiner-John W. Rollins 58) Field of Search ................ 540/109, 110; 514/169, Assistant Examiner-James D. Wilson 514/170,356 Attorney, Agent, or Firm-Burns, Doane, Swecker & Mathis 56) References Cited 57 ABSTRACT U.S. PATENT DOCUMENTS Compounds of the formula 3,987,175 10/1976 Cousse ................................ 54.6/316 4,065,566 12/1977 Bodor.................................... 560/40 D--DHC (I) 4,083,996 4/1978 Tanaka et al. ...................... 546/316 4,143,146 5/1979 Saari.................................... 54.6/316 and the nontoxic pharmaceutically acceptable salt 4,152,521 5/1979 Cousse et al. .. 546/316 thereof, wherein D is the residue of a centrally acting 4,157,396 6/1979 Tanaka et al. 546/316 drug containing at least one reactive functional group 4,195,984 12/1980 Stein et al. .......................... 546/323 selected from the group consisting of amino, hydroxyl, 4,479,932 10/1984 Bodor ..................................... 424/9 mercapto, carboxyl, amide and imide, said residue being 4,532,251 7/1985 Spatz ...... 54/354 characterized by the absence of a hydrogen atom from 4,540,564 9/1985 Bodor ..................................... 424/9 4,555,520 11/1985 Misra et al. ......................... 514/546 at least one of said reactive functional groups in said 4,558,150 12/1985 Gordon et al. ..................... 54.6/316 drug; n is a positive integer equal to the number of said 4,727,079 2/1988 Bodor .................................. 514/307 functional groups from which a hydrogen atom is ab 5,087,618 2/1992 Bodor .................................... 514/45 (Abstract continued on next page.) 5,389,623 Page 2 sent; and DHC) is the reduced, biooxidizable, blood then the alkylene groups can be the same or different brain barrier penetrating lipoidal form of a dihy and the Ro radicals can be the same or different; said dropyridine-pyridinium salt redox carrier, said carrier bivalent radical being so positioned that the terminal comprising a bivalent radical of the formula carbonyl function of the bivalent radical is linked to the drug residue while the terminal amino function of the O bivalent radical is linked to the remaining portion of the I carrier moiety; are adapted for the site-specific/sus t-calypeNH; tained delivery of centrally acting drugs to the brain. R The corresponding pyridinium salt type drug/carrier wherein the alkylene group can be straight or branched entities D-(-QC) qY are also disclosed. and can contain 1 to 3 carbon atoms; R is a radical identical to the corresponding portion of a natural amino acid; and p is 1 or 2, provided that, when p is 2, 28 Claims, No Drawings 5,389,623 1. 2 barrier, BBB. Site-specific delivery and sustained deliv REDOX CARRIERS FOR BRAN-SPECIFIC ORUG ery of drugs to the brain are even more difficult. DELIVERY It has been previously suggested to deliver a drug species, specifically N-methylpyridinium-2-carbaldox CROSS-REFERENCE TO RELATED 5 ime chloride (2-PAM), into the brain, the active nucleus APPLICATIONS of which in and of itself constitutes a quaternary pyri This application is a division of application Ser. No. dinium salt, by way of the dihydropyridine latentiated 07/295,663, filed Jan. 11, 1989, now U.S. Pat. No. prodrug form thereof. Such approach was conspicu 5,087,618, which is a division of application Ser. No. ously delimited to relatively small molecule quaternary 06/666,210, filed Oct. 29, 1984, now U.S. Pat. No. 10 pyridinium ring-containing drug species and did not 4,829,070, which is a continuation-in-part of my earlier provide the overall ideal result of brain-specific, sus applications Ser. No. 06/379,316, filed May 18, 1982, tained release of the desired drug, with concomitant now U.S. Pat. No. 4,479,932; Ser. No. 06/461,543, filed rapid elimination from the general circulation, en Jan. 27, 1983, abandoned in favor of Ser. No. hanced drug efficacy and decreased toxicity. Hence, no 06/733,463, filed May 13, 1985, now U.S. Pat. No. 15 "trapping” in the brain of the 2-PAM formed in situ 4,727,079; Ser. No. 06/475,493, filed Mar. 15, 1983, now resulted, and obviously no brain-specific, sustained de U.S. Pat. No. 4,622,218, and Ser. No. 06/515,382, filed livery occurred as any consequence thereof: the 2-PAM Jul. 22, 1983, now U.S. Pat. No. 4,540,564. Each of said was eliminated as fast from the brain as it was from the earlier applications is hereby expressly incorporated by general circulation and other organs. Compare U.S. reference in its entirely and relied upon. 20 Pat. Nos. 3,929, 813 and 3,962,447; Bodor et al., J. Pharm. Sci, 67, No. 5, pp. 685-687 (1978); Bodor et al, FIELD OF THE INVENTION Science, Vol. 190 (1975), pp. 155-156; Shek, Higuchi The present invention relates to a dihydropyridine/- and Bodor, J. Med. Chem, Vol. 19 (1976), pp. 113-117. pyridinium salt type of redox system for the site-specific A more recent extension of this approach is described or sustained delivery (or both) of a wide variety of drug 25 by Brewster, Dissertation Abstracts International, Vol. species to the brain. More especially, this invention 43, No. 09, March 1983, p. 2910B. It has a also been relates to the discovery that a biologically active com speculated to deliver, e.g., an antitumor agent, into the pound coupled to a lipoidal carrier moiety comprising a brain by utilizing a dihydropyridine/pyridinium redox dihydropyridine nucleus readily and easily penetrates carrier moiety therefor, but this particular hypothesis the blood-brain barrier (“BBB”) and attains increased 30 necessarily entails derivatizing the dihydropyridine/- levels of concentration in the brain; oxidation of the pyridinium carrier with a substituent itself critically dihydropyridine carrier moiety in vivo to the ionic designed to control the release rate of the active drug pyridinium salt prevents its elimination from the brain, species itself; Bodor et al., J. Pharm. Sci, supra. See also while elimination from the general circulation is accel Bodor, "Novel Approaches for the Design of Mem erated, resulting in significant and prolongedly sus 35 brane Transport Properties of Drugs', in Design of tained brain-specific drug activity, whether ascribable Biopharmaceutical Properties Through Prodrugs and Ana to the cleavage of the drug/quaternary entity and sus logs, Roche, E. B. (ed.), APhAAcademy of Pharmaceu tained release of the drug in the brain and/or to the tical Sciences, Washington, D.C., pp. 98-135 (1976). drug/quaternary itself. More recently, the present inventor and his cowork ers, in Bodor et al, Science, Vol. 214, December 18, BACKGROUND OF THE INVENTION 1981, pp. 1370-1372, have reported on site-specific sus The delivery of drug species to the brain is ofttimes tained release of drugs to the brain. The Science publica seriously limited by transport and metabolism factors tion outlines a scheme for specific and sustained deliv and, more specifically, by the functional barrier of the ery of drug species to the brain, as depicted in the fol endothelial brain capillary wall deemed the blood-brain lowing Scheme: SCHEME (D) + (QC)+-Eš s (D-QC* section s(D-DHC) / DELVERY TO BODY ELMINATION D-DHC D-DHC) IN CIRCULATORY SYSTEM IN THE BRAIN AND ORGANS K IN VEVO K IN VIVO oxIDATION OXDATION 5,389,623 3. 4.
Load more

Recommended publications
  • Aldrich FT-IR Collection Edition I Library
    Aldrich FT-IR Collection Edition I Library Library Listing – 10,505 spectra This library is the original FT-IR spectral collection from Aldrich. It includes a wide variety of pure chemical compounds found in the Aldrich Handbook of Fine Chemicals. The Aldrich Collection of FT-IR Spectra Edition I library contains spectra of 10,505 pure compounds and is a subset of the Aldrich Collection of FT-IR Spectra Edition II library. All spectra were acquired by Sigma-Aldrich Co. and were processed by Thermo Fisher Scientific. Eight smaller Aldrich Material Specific Sub-Libraries are also available. Aldrich FT-IR Collection Edition I Index Compound Name Index Compound Name 3515 ((1R)-(ENDO,ANTI))-(+)-3- 928 (+)-LIMONENE OXIDE, 97%, BROMOCAMPHOR-8- SULFONIC MIXTURE OF CIS AND TRANS ACID, AMMONIUM SALT 209 (+)-LONGIFOLENE, 98+% 1708 ((1R)-ENDO)-(+)-3- 2283 (+)-MURAMIC ACID HYDRATE, BROMOCAMPHOR, 98% 98% 3516 ((1S)-(ENDO,ANTI))-(-)-3- 2966 (+)-N,N'- BROMOCAMPHOR-8- SULFONIC DIALLYLTARTARDIAMIDE, 99+% ACID, AMMONIUM SALT 2976 (+)-N-ACETYLMURAMIC ACID, 644 ((1S)-ENDO)-(-)-BORNEOL, 99% 97% 9587 (+)-11ALPHA-HYDROXY-17ALPHA- 965 (+)-NOE-LACTOL DIMER, 99+% METHYLTESTOSTERONE 5127 (+)-P-BROMOTETRAMISOLE 9590 (+)-11ALPHA- OXALATE, 99% HYDROXYPROGESTERONE, 95% 661 (+)-P-MENTH-1-EN-9-OL, 97%, 9588 (+)-17-METHYLTESTOSTERONE, MIXTURE OF ISOMERS 99% 730 (+)-PERSEITOL 8681 (+)-2'-DEOXYURIDINE, 99+% 7913 (+)-PILOCARPINE 7591 (+)-2,3-O-ISOPROPYLIDENE-2,3- HYDROCHLORIDE, 99% DIHYDROXY- 1,4- 5844 (+)-RUTIN HYDRATE, 95% BIS(DIPHENYLPHOSPHINO)BUT 9571 (+)-STIGMASTANOL
    [Show full text]
  • The Anxiomimetic Properties of Pentylenetetrazol in the Rat
    University of Rhode Island DigitalCommons@URI Open Access Dissertations 1980 THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT Gary Terence Shearman University of Rhode Island Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss Recommended Citation Shearman, Gary Terence, "THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT" (1980). Open Access Dissertations. Paper 165. https://digitalcommons.uri.edu/oa_diss/165 This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT BY GARY TERENCE SHEARMAN A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN PHARMACEUTICAL SCIENCES (PHARMACOLOGY AND TOXICOLOGY) UNIVERSITY OF RHODE ISLAND 19 80 DOCTOR OF PHILOSOPHY DISSERT.A.TION OF GARY TERENCE SHEAffiil.AN Approved: Dissertation Cormnittee \\ Major Professor ~~-L_-_._dd__· _... _______ _ -~ar- Dean of the Graduate School UNIVERSITY OF RHODE ISLAND 1980 ABSTRACT Investigation of the biological basis of anxiety is ham­ pered by the lack of an appropriate animal model for research purposes. There are no known drugs that cause anxiety in laboratory animals. Pentylenetetrazol (PTZ) produces intense anxiety in human volunteers (Rodin, 1958; Rodin and Calhoun, 1970). Therefore, it was the major objective of this disser- tation to test the hypothesis that the discriminative stimu­ lus produced by PTZ in the rat was related to its anxiogenic action in man. It was also an objective to suggest the neuro- chemical basis for the discriminative stimulus property of PTZ through appropriate drug interactions.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Aldrich Raman
    Aldrich Raman Library Listing – 14,033 spectra This library represents the most comprehensive collection of FT-Raman spectral references available. It contains many common chemicals found in the Aldrich Handbook of Fine Chemicals. To create the Aldrich Raman Condensed Phase Library, 14,033 compounds found in the Aldrich Collection of FT-IR Spectra Edition II Library were excited with an Nd:YVO4 laser (1064 nm) using laser powers between 400 - 600 mW, measured at the sample. A Thermo FT-Raman spectrometer (with a Ge detector) was used to collect the Raman spectra. The spectra were saved in Raman Shift format. Aldrich Raman Index Compound Name Index Compound Name 4803 ((1R)-(ENDO,ANTI))-(+)-3- 4246 (+)-3-ISOPROPYL-7A- BROMOCAMPHOR-8- SULFONIC METHYLTETRAHYDRO- ACID, AMMONIUM SALT PYRROLO(2,1-B)OXAZOL-5(6H)- 2207 ((1R)-ENDO)-(+)-3- ONE, BROMOCAMPHOR, 98% 12568 (+)-4-CHOLESTEN-3-ONE, 98% 4804 ((1S)-(ENDO,ANTI))-(-)-3- 3774 (+)-5,6-O-CYCLOHEXYLIDENE-L- BROMOCAMPHOR-8- SULFONIC ASCORBIC ACID, 98% ACID, AMMONIUM SALT 11632 (+)-5-BROMO-2'-DEOXYURIDINE, 2208 ((1S)-ENDO)-(-)-3- 97% BROMOCAMPHOR, 98% 11634 (+)-5-FLUORODEOXYURIDINE, 769 ((1S)-ENDO)-(-)-BORNEOL, 99% 98+% 13454 ((2S,3S)-(+)- 11633 (+)-5-IODO-2'-DEOXYURIDINE, 98% BIS(DIPHENYLPHOSPHINO)- 4228 (+)-6-AMINOPENICILLANIC ACID, BUTANE)(N3-ALLYL)PD(II) CL04, 96% 97 8167 (+)-6-METHOXY-ALPHA-METHYL- 10297 ((3- 2- NAPHTHALENEACETIC ACID, DIMETHYLAMINO)PROPYL)TRIPH 98% ENYL- PHOSPHONIUM BROMIDE, 12586 (+)-ANDROSTA-1,4-DIENE-3,17- 99% DIONE, 98% 13458 ((R)-(+)-2,2'- 963 (+)-ARABINOGALACTAN BIS(DIPHENYLPHOSPHINO)-1,1'-
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Cogentin (Benztropine Mesylate) Injection Label
    COGENTIN® (benztropine mesylate injection) Rx Only DESCRIPTION Benztropine mesylate is a synthetic compound containing structural features found in atropine and diphenhydramine. It is designated chemically as 8-azabicyclo[3.2.1] octane, 3-(diphenylmethoxy)-,endo, methanesulfonate. Its empirical formula is C21H25NO•CH4O3S, and its structural formula is: Benztropine mesylate is a crystalline white powder, very soluble in water, and has a molecular weight of 403.54. COGENTIN (benztropine mesylate) is supplied as a sterile injection for intravenous and intramuscular use. Each milliliter of the injection contains: Benztropine mesylate…………………………………………………………………..1 mg Sodium chloride……………………………………………………….........................9 mg Water for injection q.s…………………………………………………………………..1 mL ACTIONS COGENTIN possesses both anticholinergic and antihistaminic effects, although only the former have been established as therapeutically significant in the management of parkinsonism. Page 1 of 7 Reference ID: 3296967 In the isolated guinea pig ileum, the anticholinergic activity of this drug is about equal to that of atropine; however, when administered orally to unanesthetized cats, it is only about half as active as atropine. In laboratory animals, its antihistaminic activity and duration of action approach those of pyrilamine maleate. INDICATIONS For use as an adjunct in the therapy of all forms of parkinsonism (see DOSAGE AND ADMINISTRATION). Useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see PRECAUTIONS) due to neuroleptic drugs (e.g., phenothiazines). CONTRAINDICATIONS Hypersensitivity to any component of COGENTIN injection. Because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients. WARNINGS Safe use in pregnancy has not been established.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]